Biogen completes acquisition of RayThera, advancing immunology pipeline with Phase 1 lead program
Biogen has finalized its acquisition of RayThera Inc., a biotech company specializing in small-molecule therapies for immunology. This deal strengthens Biogen’s immunology portfolio by adding multiple assets aimed at treating immune-related condition...
